# US 2023/0406935 A1 · Fc binding fragments comprising a pd-l1 antigen-binding site

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0406935 A1
- Document ID: US20230406935A1
- Status: Published application
- Kind: A1
- Application number: 18/063,521
- Filed: 2022-12-08
- Published: 2023-12-21
- Earliest claimed: 2017-12-19
- Assignees: F-star Therapeutics Limited
- Applicants: F-star Therapeutics Limited
- Inventors: Mihriban Tuna; Francisca Wollerton Van Horck; Ryan Fiehler; Mustapha Faroudi; Frederick Akele; Fadi Badr; Cyril Privezentzev
- Web page: https://patentgrep.com/patent/US20230406935A1

## CPC

- C07K 16/2827: {against B7 molecules, e.g. CD80, CD86}
- C07K 16/2818: {against CD28 or CD152}
- A61K 2039/505: {comprising antibodies}
- A61K 2039/507: {Comprising a combination of two or more separate antibodies}
- C07K 2317/31: multispecific
- C07K 2317/33: Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C07K 2317/524: CH2 domain
- C07K 2317/526: CH3 domain
- C07K 2317/53: Hinge
- C07K 2317/71: Decreased effector function due to an Fc-modification
- C07K 2317/732: Antibody-dependent cellular cytotoxicity [ADCC]
- C07K 2317/734: Complement-dependent cytotoxicity [CDC]
- C07K 2317/74: Inducing cell proliferation
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K 2318/20: Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The application relates to specific binding members which bind to programmed death-ligand 1 (PD-L1). The specific binding members preferably comprise a PD-L1 antigen-binding site located in structural loops of a constant domain of the specific binding member. The specific binding members find application, for example, in the treatment of cancer, as well as infectious diseases, inflammation, diseases and conditions associated with inflammation, and inflammatory diseases.

## Claims

### Claim 1

An antibody molecule, or fragment thereof, which binds to programmed death-ligand 1 (PD-L1), comprising a PD-L1 antigen-binding site located in a CH3 domain of the antibody molecule, or fragment thereof, wherein the PD-L1 binding site comprises:
(i) a first sequence located in the AB structural loop at positions 14 to 18 of the CH3 domain, wherein the antibody molecule, or fragment thereof, comprises an amino acid deletion at position 14, 15 or 16 of the CH3 domain, and wherein the first sequence consists of:
(a) amino acid sequence SGYW (SEQ ID NO: 23), or
(b) a variant of SEQ ID NO: 23, wherein
the serine (S) is substituted with amino acid A, E, F, G, H, I, L, P, R, T, V, or Y, and/or
the glycine (G) is substituted with amino acid A, D, E, F, H, K, L, N, P, R, T, V, or Y;
(ii) a second sequence located in the CD structural loop at positions 45.1 to 78 of the CH3 domain, wherein the second sequence consists of:
(a) amino acid sequence EPQYWA (SEQ ID NO: 11), or
(b) a variant of SEQ ID NO: 11, wherein
the glutamic acid (E) is substituted with amino acid A, G, H, I, L, N, Q, R, S, or W, and/or
the proline (P) is substituted with amino acid A, D, E, G, H, N, Q, W, or Y, and/or
the glutamine (Q) is substituted with amino acid H, or N, and/or
the tyrosine (Y) is substituted with amino acid A, D, H, T, or V, and/or
the alanine (A) is substituted with amino acid D, E, G, L, R, S, or W; and
(iii) a third sequence located in the EF structural loop at positions 92 to 100 of the CH3 domain, wherein the third sequence consists of:
(a) amino acid sequence SNWRWQMDD (SEQ ID NO: 19), or
(b) a variant of SEQ ID NO: 19, wherein
the serine (S) at position 92 is substituted with amino acid A, or G, and/or
the asparagine (N) at position 93 is substituted with amino acid A, E, F, G, H, I, K, L, Q, R, S, T, or Y, and/or
the glutamine (Q) at position 97 is substituted with amino acid A, D, E, F, G, H, K, L, N, R, S, or V, and/or
the methionine (M) at position 98 is substituted with amino acid F, I, L, V, W, or Y, and/or
the aspartic acid (D) at position 99 is substituted with amino acid A, I, L, R, S, T, V, W, Y, or G, and/or
the aspartic acid (D) at position 100 is substituted with amino acid A, E, F, I, K, L, N, R, V, W, or Y; and
wherein the amino acid at position 101 of the CH3 domain is valine (V), alanine (A) or is absent;
wherein the amino acid residue numbering is according to the ImMunoGeneTics (IMGT) numbering scheme; and
wherein the antibody molecule, or antigen-binding fragment thereof, is not an antibody molecule, or antigen-binding fragment thereof, which comprises a CDR-based antigen-binding site which binds Inducible T-cell COStimulator (ICOS) and a PD-L1 binding site comprising a first sequence located in the AB structural loop at positions 14 to 18 of the CH3 domain, wherein the antibody molecule, or antigen-binding fragment thereof, comprises an amino acid deletion at position 14, 15 or 16 of the CH3 domain, and wherein the first sequence consists of the sequence set forth in SEQ ID NO: 23, a second sequence located in the CD structural loop at positions 45.1 to 78 of the CH3 domain, wherein the second sequence consists of the sequence set forth in SEQ ID NO: 11, and a third sequence located in the EF structural loop at positions 92 to 100 of the CH3 domain, wherein the third sequence consists of the sequence set forth in SEQ ID NO: 31.

### Claim at position 2

-4. (canceled)

### Claim 5 (depends on 1)

The antibody molecule, or fragment thereof, according to claim 1, wherein:
(i) the first sequence has the sequence set forth in SEQ ID NO: 23, the second sequence has the sequence set forth in SEQ ID NO: 11, and the third sequence has the sequence set forth in SEQ ID NO: 19;
(ii) the first sequence has the sequence set forth in SEQ ID NO: 23, the second sequence has the sequence set forth in SEQ ID NO: 11, and the third sequence has the sequence set forth in SEQ ID NO: 27;
(iii) the first sequence has the sequence set forth in SEQ ID NO: 23, the second sequence has the sequence set forth in SEQ ID NO: 11, and the third sequence has the sequence set forth in SEQ ID NO: 35; or
(iv) the first sequence has the sequence set forth in SEQ ID NO: 23, the second sequence has the sequence set forth in SEQ ID NO: 11, and the third sequence has the sequence set forth in SEQ ID NO: 31, and the residue at position 38 of the CH3 domain of the antibody molecule, or fragment thereof, is valine (V) or alanine (A).

### Claim at position 4

-11. (canceled)

### Claim 12 (depends on 5)

The antibody molecule, or fragment thereof, according to claim 5, wherein the first sequence has the sequence set forth in SEQ ID NO: 23, the second sequence has the sequence set forth in SEQ ID NO: 11, and the third sequence has the sequence set forth in SEQ ID NO: 19.

### Claim 13 (depends on 5)

The antibody molecule, or fragment thereof, according to claim 5, wherein the first sequence has the sequence set forth in SEQ ID NO: 23, the second sequence has the sequence set forth in SEQ ID NO: 11, and the third sequence has the sequence set forth in SEQ ID NO: 27.

### Claim 14 (depends on 5)

The antibody molecule, or fragment thereof, according to claim 5, wherein the first sequence has the sequence set forth in SEQ ID NO: 23, the second sequence has the sequence set forth in SEQ ID NO: 11, and the third sequence has the sequence set forth in SEQ ID NO: 35.

### Claim 15

(canceled)

### Claim 16 (depends on 1)

The antibody molecule, or fragment thereof, according to claim 1, wherein the CH3 domain is a human IgG1 CH3 domain.

### Claim 17 (depends on 1)

The antibody molecule, or fragment thereof, according to claim 1, wherein the amino acid at position 38 of the CH3 domain is a valine or an alanine residue.

### Claim 18 (depends on 1)

The antibody molecule, or fragment thereof, according to claim 1, wherein the amino acid at position 38 of the CH3 domain is an alanine residue.

### Claim 19 (depends on 1)

The antibody molecule, or fragment thereof, according to claim 1, wherein the antibody molecule, or fragment thereof, comprises the CH3 domain set forth in SEQ ID NO: 24, 28, 36, or 39.

### Claim 20

(canceled)

### Claim 21 (depends on 19)

The antibody molecule, or fragment thereof, according to claim 19, wherein the antibody molecule, or fragment thereof, further comprises a CH2 domain.

### Claim at position 15

-23. (canceled)

### Claim 24 (depends on 21)

The antibody molecule, or fragment thereof, according to claim 21, wherein the CH2 domain has the sequence set forth in SEQ ID NO: 5, 6, or 82.

### Claim 25 (depends on 21)

The antibody molecule, or fragment thereof, according to claim 21, wherein the antibody molecule, or fragment thereof, further comprises an immunoglobulin hinge region, or part thereof, at the N-terminus of the CH2 domain.

### Claim at position 18

-27. (canceled)

### Claim 28 (depends on 25)

The antibody molecule, or fragment thereof, according to claim 25, wherein the hinge region comprises or consists of the sequence set forth in SEQ ID NO: 7.

### Claim 29 (depends on 25)

The antibody molecule, or fragment thereof, according to claim 25, wherein the antibody molecule, or fragment thereof, comprises or consists of the sequence set forth in SEQ ID NO: 25, 26, 29, 30, 37, 38, 40, or 41.

### Claim 30

(canceled)

### Claim 31 (depends on 1)

The antibody molecule, or fragment thereof, according to claim 1, wherein the antibody molecule, or fragment thereof, further comprises a second antigen-binding site.

### Claim 32 (depends on 5)

The antibody molecule, or fragment thereof, according to claim 5, wherein the antibody molecule, or fragment thereof, further comprises a second antigen-binding site, wherein the second antigen-binding site is a CDR-based antigen-binding site.

### Claim at position 24

-35. (canceled)

### Claim 36 (depends on 32)

The antibody molecule, or fragment thereof, according to claim 32, wherein the CDR-based antigen-binding site binds to a checkpoint inhibitor, costimulatory molecule, or tumour-associated antigen.

### Claim at position 26

-39. (canceled)

### Claim 40 (depends on 31)

The antibody molecule, or fragment thereof, according to claim 31, wherein the second antigen-binding site is a CDR-based antigen-binding site, and wherein the antibody molecule, or fragment thereof, is conjugated to an immune system modulator, cytotoxic molecule, radioisotope, or detectable label.

### Claim at position 28

-55. (canceled)

### Claim 56 (depends on 5)

The antibody molecule, or fragment thereof, according to claim 5, wherein the first sequence has the sequence set forth in SEQ ID NO: 23, the second sequence has the sequence set forth in SEQ ID NO: 11, and the third sequence has the sequence set forth in SEQ ID NO: 31, and the residue at position 38 of the CH3 domain of the antibody molecule, or fragment thereof, is valine (V) or alanine (A).

### Claim 57 (depends on 19)

The antibody molecule, or fragment thereof, according to claim 19, wherein the lysine residue (K) at the immediate C-terminus of the sequence shown in SEQ ID NO: 24, 28, 36, or 39 has been deleted.
